Dave: well, I am going to find it unless someone else finds it first. Biotech is risky, but the orphan strategy of AMBS is the plan for a reason. Just wanted to temper your soft bash message with the reality that AMBS has an orphan strategy and success is usually much better in that environment, which will lead to better success outside of orphan designations as the data builds.